NCT01755598View on ClinicalTrials.gov

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

3,575

Participants

Timeline

Start Date

August 19, 2014

Primary Completion Date

November 16, 2018

Study Completion Date

November 16, 2018

Conditions
TuberculosisTuberculosis Vaccines
Interventions
BIOLOGICAL

GSK Biologicals' investigational TB vaccine (GSK692342)

2 doses administered intramuscularly in the deltoid region of the arm.

BIOLOGICAL

Placebo

2 doses administered intramuscularly in the deltoid region of the arm.

Trial Locations (9)

2013

GSK Investigational Site, Soweto

2571

GSK Investigational Site, Klerksdorp

6850

GSK Investigational Site, Worcester

7530

GSK Investigational Site, Cape Town

7925

GSK Investigational Site, Cape Town

Unknown

GSK Investigational Site, Kisumu

GSK Investigational Site, Western Cape

GSK Investigational Site, Lusaka

0152

GSK Investigational Site, Pretoria

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Aeras
All Listed Sponsors
collaborator

Aeras

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT01755598 - Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults | Biotech Hunter | Biotech Hunter